18F-FDG PET/CT for initial staging in breast cancer patients

• Verfasst von: Krammer, Julia [VerfasserIn]
• Verfasst von: Schnitzer, Andreas [VerfasserIn]
• Verfasst von: Kaiser, Clemens G. [VerfasserIn]
• Verfasst von: Büsing, Karen-Anett [VerfasserIn]
• Verfasst von: Sperk, Elena [VerfasserIn]
• Verfasst von: Brade, Joachim [VerfasserIn]
• Verfasst von: Wasgindt, Sabine [VerfasserIn]
• Verfasst von: Sütterlin, Marc [VerfasserIn]
• Verfasst von: Schönberg, Stefan [VerfasserIn]
• Verfasst von: Wasser, Klaus [VerfasserIn]
• Titel: 18F-FDG PET/CT for initial staging in breast cancer patients
• Titelzusatz: Is there a relevant impact on treatment planning compared to conventional staging modalities?
• Verf.angabe: J. Krammer, A. Schnitzer, C.G. Kaiser, K.A. Buesing, E. Sperk, J. Brade, S. Wasgindt, M. Suetterlin, S.O. Schoenberg, E.J. Sutton, K. Wasser
• E-Jahr: 2015
• Jahr: 15 February 2015
• Umfang: 10 S.
• Fussnoten: Gesehen am 19.02.2018 ; Im Titel ist "18" hochgestellt
• Titel Quelle: Enthalten in: European radiology
• Ort Quelle: Berlin : Springer, 1991
• Jahr Quelle: 2015
• Band/Heft Quelle: 25(2015), 8, Seite 2460-2469
• ISSN Quelle: 1432-1084
• ISSN Quelle: 1613-3757
• DOI: doi:10.1007/s00330-015-3630-6
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1569954720

Abstract

Objective: To evaluate the impact of whole-body 18 F-FDG PET/CT on initial staging of breast cancer in comparison to conventional staging modalities. Methods: This study included 102 breast cancer patients, 101 patients were eligible for evaluation. Preoperative whole-body staging with PET/CT was performed in patients with clinical stage ≥ T2 tumours or positive local lymph nodes (n = 91). Postoperative PET/CT was performed in patients without these criteria but positive sentinel lymph node biopsy (n = 10). All patients underwent PET/CT and a conventional staging algorithm, which included bone scan, chest X-ray and abdominal ultrasound. PET/CT findings were compared to conventional staging and the impact on therapeutic management was evaluated. Results: PET/CT led to an upgrade of the N or M stage in overall 19 patients (19 %) and newly identified manifestation of breast cancer in two patients (2 %). PET/CT findings caused a change in treatment of 11 patients (11 %). This is within the range of recent studies, all applying conventional inclusion criteria based on the initial T and N status. Conclusions: PET/CT has a relevant impact on initial staging and treatment of breast cancer when compared to conventional modalities. Further studies should assess inclusion criteria beyond the conventional T and N status, e.g. tumour grading and receptor status.